March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be integrated into DeepHealth, RadNet’s wholly owned subsidiary. The acquisition further expands DeepHealth’s AI-powered health informatics solutions and services, making it the largest provider of radiology clinical AI solutions worldwide.1
With more than 130 professionals, Gleamer is a cloud-first, radiology AI company serving more than 700 customer contracts in 44 countries. Its broad multimodality portfolio of FDA-cleared and CE-marked clinical AI and workflow solutions for musculoskeletal, breast, lung and neurologic applications is designed to improve quality of care while reducing the radiologist workload. Gleamer’s customers include hospitals, imaging centers and healthcare systems and its cloud platform drives a SaaS ARR business model.
Dr. Howard Berger, president and CEO of RadNet, commented: “As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows — particularly routine imaging such as X-ray, Ultrasound and Mammography — is becoming essential to sustaining access, efficiency and quality of care. For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics.”
The integration of Gleamer’s portfolio with DeepHealth’s clinical AI suites of solutions for breast, chest, neuro, prostate and thyroid creates a comprehensive portfolio. The combined portfolio supports screening, detection, interpretation and follow-up across many of the most prevalent cancer types, as well as neurodegenerative and musculoskeletal conditions. With the inclusion of Gleamer’s products, DeepHealth is now a worldwide leader in clinical AI solutions across MR, CT, X-ray, Mammography and Ultrasound modalities.
“Joining DeepHealth marks an exciting new chapter for our business and team members,” said Christian Allouche, co-founder and CEO of Gleamer. “Our team has been driven by a mission to improve patient care and access, and we are proud of the impact we have had on our customers and patients worldwide. By combining our AI capabilities, product portfolio and strong commercial team with that of DeepHealth, we are poised to shape the future of intelligent imaging at scale.”
"This acquisition brings together two leaders on strong growth trajectories to create a new standard of AI-powered care. By building on our combined strengths, we are redefining how imaging is delivered, at scale, with intelligence and automation, to advance access and efficiency while improving experiences and outcomes for patients and providers worldwide,” said Kees Wesdorp, president and CEO of RadNet’s Digital Health Division, DeepHealth.
Gleamer’s capabilities in automated reporting, already deployed in Europe, combined with DeepHealth’s AI and informatics portfolio, bring clinical, generative and agentic AI and imaging informatics together into an integrated offering. With this extensive expertise, DeepHealth is uniquely positioned to enable more standardized interpretation, automated draft reporting and scalable diagnostic pathways.
Additionally, deploying Gleamer’s radiology AI and workflow capabilities across RadNet’s imaging network is expected to create measurable productivity gains, particularly in x-ray, which accounts for almost 25% of RadNet’s imaging volume. RadNet intends to implement an end-to-end AI-enabled workflow that begins with triaging critical findings to accelerate the interpretation of the most urgent cases. The acquisition will also accelerate the introduction of draft reporting capabilities, allowing radiologists to increase reading volumes with greater accuracy and standardization. This approach will enable RadNet to optimize internal resource utilization, resulting in improved operational and cost efficiencies.
- DeepHealth and Gleamer have a combined installed base of 2,700+ customer contracts across more than 50 countries, a comprehensive portfolio including 26 FDA-cleared and 22 CE-marked devices supporting 75+ indications, and a global footprint with 550+ employees across four continents. DeepHealth with Gleamer together anticipate achieving ARR approaching or exceeding $140 million by the end of 2026. We believe that these metrics make DeepHealth the leader in providing clinical radiology AI solutions worldwide.
March 11, 2026 
